Skip to main content
Premium Trial:

Request an Annual Quote

Celera Predicts Online Business to Turn a Profit in 2002 as it Aims for Future in Drug Discovery

SAN FRANCISCO, Jan. 10 - Celera Genomics received a boost for its drug discovery ambitions with a milestone payment from Aventis Pharma for their joint Cathepsin S research, the company said on Thursday.

 

The payment, a fourth and final research milestone in a collaboration with Aventis to develop inflammation and autoimmune disease drugs around Cathepsin S inhibitors, was part of an agreement Aventis had with Axys Pharmaceuticals, which Celera acquired in Nov.

 

["This] fast-forwards Celera into the therapeutics business," Michael Venuti, general manager of Celera's South San Francisco facility, said at the 20th annual JPMorgan H&Q Healthcare Conference, which ended today.

 

The push into drug development comes at a time when Celera's traditional data programs are growing and turning towards profitability.

 

The genomics and proteomics data being generated by the company will reach the double- or triple-digit petabyte level and Celera's online information business will turn a profit by the end of 2002, said company president Craig Venter.

 

Money from the online business will help fund drug discovery, Applera CEO Tony White said.

 

"Information will never be a multibillion dollar business," said White. "The goal was always to become a user of our data. Celera is in the transformation stage. Information is a means to an end. We have to get busy to retool to become a credible drug discovery company."

 

Retooling also includes working out storage challenges for the company's rapidly expanding data, said Venter.

 

"[We're] keeping things segmented and talking to all the major computer players" about solutions, said Venter, who added that he was also talking to Oracle CEO Larry Ellison about new approaches to data storage.

 

 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.